Skip to main content
Premium Trial:

Request an Annual Quote

GeneData to Provide Phylosopher Software to Novartis

NEW YORK, March 27 – Database and bioinformatics company GeneData said Tuesday it entered a multi-year collaboration to supply its Phylospher comparative genomics software for the study of pathogens to Novartis Pharma, extending a relationship between the two companies that began three years ago.

In February, GeneData announced that Novartis had licensed its Expressionist microarray data analysis system. 

Under the terms of the agreement, GeneData will install its Phylosopher software throughout Novartis. The software system allows researchers to analyze the genomes of pathogens by comparing them with genomes of other organisms.

GeneData said its software is capable of characterizing genes, proteins, and pathways to lead to the development of new anti-microbial drugs as well as allowing researchers to study mechanisms-of-action, identifying pathogenic factors in specific species, and evaluating drug leads.

Financial terms were not disclosed.

Last week, GeneData said Japan’s National Institute of Technology and evaluation purchased the Phylospher software to help annotate genomes of various microbes, including two heat-resistant microbes it has already sequenced.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.